CA-VISA-INC
23.5.2023 09:01:35 CEST | Business Wire | Press release
Visa Inc. (NYSE: V), a global leader in digital payments, today announced that it plans to open a new global Technology and Product Hub in Poland that will be the first of its kind for Visa in Central and Eastern Europe. The Hub will house as many as 1,500 new tech and product hires over the next few years, as Visa invests worldwide to support its 24/7 development model for innovation and drives continued rapid growth in digital commerce and payments.
“Poland’s highly skilled workforce and vibrant IT sector make it an ideal location for us to recruit and collaborate with partners and businesses to develop new payment solutions,” said Rajat Taneja, President, Technology, Visa. “The next wave of our product and innovation roadmap is even more exciting as we focus on the next generation of AI, cybersecurity and the resilience and availability of our network for all who depend on it.”
Poland will serve as Visa’s fifth major strategic global Technology and Product Hub. As a growing location for top technology talent, it builds on Visa’s commitment to innovation and investment in the European region, and in Poland, in particular. Visa will find new ways to harness emerging talent in the region, accelerate product development and innovate at scale to bring value to consumers, clients, buyers and sellers around the world.
“As a global company that does business in more than 200 countries and territories, it is important to us to invest in local talent, creating regional tech hubs that allow us to serve our global customer base better than ever before,” said Charlotte Hogg, CEO, Visa, Europe. “We are committed to diversity and inclusion and ensuring that as Visa grows, it reflects the wide range of perspectives that make up the communities where we live and work. In Poland, this will mean bringing on board a diverse talent pool and welcoming talent from Ukraine and other parts of the region.”
“It is exceptionally good news that Visa, with its unique global experience and know-how, has chosen our country out of all possible locations, thus building Poland's position as the best place for investments in the new technology sector,” said Prime Minister of Poland, Mateusz Morawiecki. “Some of the factors that pointed to Poland as a location for this investment were the high qualifications of our IT staff and the significant pool of talent on the labor market. We have great potential to bring highly innovative investments to our country."
Visa has been at the forefront of digital payments for more than 60 years, operating in Poland since 1995. The first payment card in Poland was a Visa card and since the early digital days, Visa innovations have underpinned many of the ways that consumers and merchants pay and are paid. With Visa as a driving force in digital payments, Poland became the first market in the world to achieve 100% contactless availability.
Visa recognizes the critical role that digital skills play in the modern economy and is committed to supporting the EU’s efforts to build a more competitive and digitally savvy workforce.1 This investment underscores Visa’s pledge to promote digital inclusion and empower individuals to thrive in the digital age.
More details on Visa’s new global Technology and Product Hub will be shared in the coming months. Open roles in Poland can be found here.
About Visa Inc.
Visa (NYSE: V) is a world leader in digital payments, facilitating payments transactions between consumers, merchants, financial institutions and government entities across more than 200 countries and territories. Our mission is to connect the world through the most innovative, convenient, reliable and secure payments network, enabling individuals, businesses and economies to thrive. We believe that economies that include everyone everywhere, uplift everyone everywhere and see access as foundational to the future of money movement. Learn more at Visa.com.
1 Through the Digital Decade the EU aims to ensure that 20 million ICT specialists are in employment in the EU by 2030. https://ec.europa.eu/commission/presscorner/detail/en/ip_23_2246
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230523005524/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 15:00:00 CEST | Press release
Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release
Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom